Protocol One Independent reference

Understand the evidence.
Compare care and costs.

A free, plain-language guide to peptides and GLP-1 care. See what human research says, what remains uncertain, and what to compare before you decide what to read next.

Choose my next step

Start with a topic, compare care and costs, or read the evidence.

Three ways in

What are you here to do?

01 Learn

Understand peptides

Start with a clear explanation, then explore what is known and what is still uncertain.

Explore the basics 02 Compare

Compare care and costs

Review GLP-1 care options, pricing details, and the questions worth checking before you pay.

See the provider comparison 03 Evidence

Read the evidence

Use BPC-157 as an example: see the research status, limited human evidence, and regulatory caveat.

Read the BPC-157 overview

Document review

Checking a source document?

This is a document review aid only. It does not verify a product or provide safety clearance for use.

Open the document check

The Directory

Editorial reading order

These tiers are Protocol One's editorial reading order, not evidence grades, safety ratings, or treatment rankings. Each entry should be read for its own human evidence and regulatory status. Use the filters to browse topics.

S Editorial S · featured reads

Recovery

BPC-157

Editorial S-Tier · featured read

Human evidence limited · not FDA-approved for human use

Body Protection Compound 157. An editorial favorite for exploring recovery research, with important gaps in human evidence.

Weight Loss

Tirzepatide

S-Tier · FDA-approved

Active ingredient in Mounjaro and Zepbound. Dual GLP-1 + GIP agonist with a quiet liver story.

Weight Loss

Semaglutide

S-Tier · FDA-approved

Active ingredient in Ozempic and Wegovy. The molecule that started the GLP-1 conversation, plus cardiovascular-outcomes data most coverage misses.

Weight Loss · NEW READOUT

Retatrutide

S-Tier (Phase 3 positive) · NDA pending

Triple-agonist GLP-1 + GIP + glucagon. TRIUMPH-1 pivotal Phase 3 readout dropped in May 2026: 28.3% body weight loss over 80 weeks at the high dose, 45.3% of patients lost 30% or more of their body weight. Biggest GLP-1 number on the board. Not yet available - wait, don't source.

A Editorial A · selected reads

Recovery

TB-500

A-Tier · Rx via compounding

Thymosin Beta-4 fragment. Half of the "Wolverine blend" - paired with BPC-157 in the most-discussed recovery protocol on the internet.

Skin & Recovery

GHK-Cu

A-Tier · Topical OTC / Rx injectable

Copper-binding tripeptide. Strong topical evidence; injectable use is biohacker territory.

Cognitive (intl)

Cerebrolysin

A-Tier (intl) · Not FDA-approved

Porcine-brain-derived peptide extract. Approved as a prescription drug in 50+ countries. Strongest cognitive-peptide evidence base; sourcing in the US is the hard part.

Sexual Health